Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22932551 | 0.87 | MEN1 (0.42) | TSHRMEN1THRBHTTKMT2A | |
| SCHEMBL23075826 | 0.82 | ADRB2 (0.42) | TSHRMEN1THRBHTTKMT2A | |
| SCHEMBL22930357 | 0.77 | HRH3 (0.38) | — | |
| SCHEMBL22930363 | 0.77 | — | — | |
| SCHEMBL22932435 | 0.76 | — | — | |
| SCHEMBL24897598 | 0.76 | KDM4E (0.41) | TSHRMEN1THRBHTTKMT2A | |
| SCHEMBL5116276 | 0.75 | ALDH1A1 (0.38) | TSHRHTTKMT2AMAPTGAA | |
| SCHEMBL22921089 | 0.74 | KDM4E (0.39) | TSHRMEN1THRBHTTKMT2A | |
| SCHEMBL27802036 | 0.74 | TSHR (0.48) | TSHRMEN1THRBHTTKMT2A | |
| SCHEMBL23076082 | 0.72 | KDM4E (0.41) | TSHRMEN1THRBHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230019060-A1 | HETEROCYCLIC COMPOUNDS FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230019060-A1 | HETEROCYCLIC COMPOUNDS FOR MEDICAL TREATMENT | CRBN, MDM2, RBX1 | TSHR 3515/4885MEN1 1285/4885THRB 2466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.